Idenix Targets HIV Partner By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
IDX899 boasts positive Phase I/II prospects and potential as a fixed-dose combo.
You may also be interested in...
GSK Pays $34 Million Upfront To License Idenix’s Phase II HIV Candidate
Idenix says deal will give it the ability to focus on trio of hepatitis C programs.
GSK Pays $34 Million Upfront To License Idenix’s Phase II HIV Candidate
Idenix says deal will give it the ability to focus on trio of hepatitis C programs.
Ardea’s HIV Drug Shows Once-Daily Potential In Phase II
NNRTI targets treatment-naive patients who cannot take BMS’ Sustiva, CEO says.